Advertisement

Topics

Clinical Trials About "Deferasirox Healthy" RSS

20:47 EDT 19th October 2018 | BioPortfolio

We list hundreds of Clinical Trials about "Deferasirox Healthy" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Deferasirox Healthy" on BioPortfolio

We have published hundreds of Deferasirox Healthy news stories on BioPortfolio along with dozens of Deferasirox Healthy Clinical Trials and PubMed Articles about Deferasirox Healthy for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Deferasirox Healthy Companies in our database. You can also find out about relevant Deferasirox Healthy Drugs and Medications on this site too.

Showing "Deferasirox Healthy" Clinical Trials 1–25 of 12,000+

Relevant

Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.

This study is to assess the pharmacokinetics of deferasirox in hepatically impaired patients compared to healthy volunteers.


Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam

This is a study to investigate the pharmacokinetics of deferasirox

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study

The purpose of this study is to determine if the addition of the medication, deferasirox, to standard antifungal therapy for the infection, mucormycosis, is safe and effective


Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec

This study will assess the safety and efficacy of deferasirox in patients with cardiac MRI T2* < 20 msec.

Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Other Patients With Rare Chronic Anemia and Transfusional Iron Overload

A 1-year randomized Phase II core trial was conducted to investigate the efficacy of deferasirox in regularly transfused patients with β-thalassemia and other rare chronic anemia 2 years of age and older. Patients who successfully completed this main trial may continue in this extension trial to receive chelation therapy with deferasirox for up to 3 years. The objective of this study is to assess the long-term safety and efficacy of deferasirox in these patient groups.

Safety, Tolerability, and Efficacy of Deferasirox in MDS

Open label, single arm study on Deferasirox treatment in MDS patients with chronic transfusional hemosiderosis. Patients receive daily oral dosis of Deferasirox in order to eliminate the quantity of iron administered during transfusions and, if needed, to reduce the overload of already present iron. After an screening phase in which patients are evaluated according to eligibility criteria, a one year treatment phase foresees monthly visits to evaluate safety and efficac...

Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Thirty patients will be enrolled into this open-label, single-arm trial designed to assess the safety and tolerability of oral deferasirox in adult transfusion dependent myelodysplastic syndrome (MDS) patients with iron overload. Patients enrolled in this study will have low or intermediate (INT-1) risk MDS per International Prognostic Scoring System (IPSS) criteria. All patients will initiate treatment with 20mg/kg/day deferasirox. Deferasirox will be administered orally onc...

Pilot Study for Patients With Poor Response to Deferasirox

This purpose of this study is to understand the differences between people who have a good response to deferasirox (exjade) compared to people who have a poor response to this medication when used for transfusion-dependent iron overload. The hypothesis is that patients with poor responses have physiologic barriers to deferasirox that may include absorption, pharmacokinetics of drug metabolism, hepatic clearance and/or genetic factors.

Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis

The study employs an interventional, prospective, single arm, open label, global, multicenter,non-randomized trial design to monitor and assess the safety profile of the crushed deferasirox FCT in pediatric patients between age ≥2 to

An Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Patients With Transfusional Iron Overload

A 1-year randomized Phase III core trial using deferoxamine as the comparator was conducted to investigate the efficacy of deferasirox in regularly transfused patients with β-thalassemia 2 years of age and older. Patients who successfully completed this main trial may continue in this extension trial to receive chelation therapy with deferasirox for up to 3 years. The objective of this study is to assess the efficacy and long-term safety of deferasirox in regularly tran...

Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox

This study will observe patients with transfusional hemosiderosis treated with deferasirox in actual practice setting.

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

RATIONALE: Low dose deferasirox may be safe and effective in treating patients who have undergone hematopoietic stem cell transplant and have iron overload. PURPOSE: This pilot clinical trial studies safety and tolerability of deferasirox in hematopoietic stem cell transplant recipients who have iron overload. Effect of low dose deferasirox on labile plasma iron is also examined.

Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)

To allow patients treated with deferasirox in the core study to continue iron chelation therapy for 2 years or until the drug became locally commercially available. To evaluate the long-term safety and efficacy of deferasirox by measuring treatment success, change in liver iron content (LIC) and change in serum ferritin levels. Safety was mainly assessed by incidence of adverse events (AEs)and clinically significant lab parameters.

A Two-year Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis.

The purpose of this study is to evaluate the efficacy and safety of deferasirox film coated tablet (FCT) versus phlebotomy for the management of iron overload in adults with HH at risk of iron-related morbidity. This evaluation will provide information on the two treatment options in terms of the rate of response of proportion of patients reaching the study target SF ≤ 100 μg/L and their associated safety profiles. In addition to exploring the safety and efficacy of deferas...

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

This study will examine the long-term safety and efficacy of Deferasirox in patients with sickle cell disease and iron overload from repeated blood transfusions.

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

The purpose of this trial is to examine the safety and efficacy of deferasirox in patients with Myelodysplastic Syndrome (MDS) and chronic iron overload from blood transfusions.

Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet

Study to evaluate patient preference of deferasirox FCT or deferasirox DT in patient with transfusion -dependent thalassemia or non-transfusion -dependent thalassemia as measured by preference questionnaire at Week 48

Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload

The purpose of this study is to investigate the effects of iron chelation using deferasirox in low and INT-1 risk (referring to the international prognostic scoring system, IPSS) MDS patients who show signs of iron overload due to repeated blood transfusions. This trial is not recruiting patients in the United States.

Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload

This extension study investigates the safety and efficacy of deferasirox in regularly transfused patients with β-thalassemia major. Patients who successfully completed the main trial are eligible to continue in this extension trial and receive chelation therapy with deferasirox for up to 3 years.

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

The primary purpose of this study is to evaluate the effect of deferasirox on renal hemodynamics by determining glomerular filtration rate (GFR), renal plasma flow (RPF) and filtration fraction (FF).

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

This phase II trial studies how well deferasirox works in treating patients with very low, low, or intermediate-risk anemia or myelodysplastic syndrome that depends on red blood cell transfusions. Deferasirox may treat too much iron in the blood caused by blood transfusions.

Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda

To determine the efficacy and tolerability of deferasirox in the treatment of Porphyria Cutanea Tarda. Primary objective - the elimination of all blistering within 6 months of treatment. Secondary objective - decrease in total body iron levels.

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

RATIONALE: Deferasirox may be effective in treating iron overload caused by blood transfusions in patients who have undergone donor stem cell transplant. PURPOSE: This phase II trial is studying the side effects and how well deferasirox works in treating patients with iron overload after donor stem cell transplant.

Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload

This study will evaluate the safety and efficacy of deferasirox in non-transfusion dependent thalassemia patients with iron overload. Extension Study: Patients will be treated either with active treatment (deferasirox) or placebo for 12 months (core study phase). Patients who complete the core study phase will be offered to continue their study with the active treatment (deferasirox) in a 12 months extension phase. During the core and extension, the effects of treatmen...

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

The primary purpose of this study is to prospectively assess the efficacy and safety of iron chelation therapy with deferasirox compared to placebo in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload.


More From BioPortfolio on "Deferasirox Healthy"

Advertisement
Quick Search
Advertisement
Advertisement